RE:Literally 0 tests sold?molotov421 wrote: "With the significant decline in COVID revenue in 2022, management has re-focused on its operations respecting
cancer testing and care. Consequently, the Company has one reportable operating segment, operating in two major
geographic areas, North America and Western Europe."
Aristotle and covid used to be reported under "lab operations" which apparently is no longer a thing now that covid is gone...wow!
METRICS Study Informs Expansion of StageZero's New Care Oncology Protocol 2; establishes pathway to METRICS II and Glioblastoma addition to Aristotle.
• COC clinics on path to full profitability by year end 2023
• Scaled up Aristotle/AVRT early cancer testing with Fire Fighters in the Greater Toronto Area.
• Aristotle Employer programs gaining traction.
: • .Position Aristotle + AVRT as the #1 program for early cancer detection for employers with at-risk workforces.
• Fully implement partnerships with key employer groups using Aristotle + AVRT.
• Present data and analysis with respect to at-risk workforces to demonstrate benefit of Aristotle + AVRT
• Broaden relationships with key oncologists and clinics to enhance the reach of CareOncology/Aristotle with a strong focus on Laboratory Systems and HealthCare Systems in multiple key cities.
• Continue to broaden and deepen Aristotle eg Colorectal Cancer staging, addition of Glioblastoma.